News | Treatment Planning | August 03, 2021

GenesisCare Renews RadCalc QA Software in 173 Radiation Oncology Centers

LAP announced it has strengthened its partnership with leading integrated oncology care provider, GenesisCare, to continue providing advanced treatment planning software in radiation oncology centers around the globe.

August 3, 2021 — LAP announced it has strengthened its partnership with leading integrated oncology care provider, GenesisCare, to continue providing advanced treatment planning software in radiation oncology centers around the globe.

As the complexity of treatment planning in radiation oncology increases, it is imperative for physicians and radiation therapists to have confidence in the accuracy of secondary dose verification. RadCalc’s independent 3D calculations has allowed GenesisCare and other providers a more accurate analysis of the dose being delivered to their patients with customizable automation designed to fit any clinical workflow.

GenesisCare will continue to employ RadCalc in 173 radiation oncology sites across Australia, the United Kingdom, Spain and the United States, with room for further expansion to other sites in the future. Included in the agreement is also RadCalc’s 3D premium for the UK region and GammaKnife solution.

GenesisCare is the world’s largest provider of radiotherapy – an important treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials.

“RadCalc is a comprehensive treatment plan analysis tool that ensures our patients receive the highest quality precision care and treatment plans that have the best chance of improving patient outcomes,” said Tim Fox, GenesisCare’s Global Head of Medical Physics and Clinical Technology.

With their collaboration both parties aim to enhance safety and efficiency in radiation oncology.

For more information: www.lap-laser.com

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
At the recent 2021 AAPM Meeting in July, Sun Nuclear Corporation featured its comprehensive portfolio of independent, integrated quality management solutions for radiation therapy and diagnostic imaging.
News | Quality Assurance (QA) | September 02, 2021
September 2, 2021 — At the recent 2021 AAPM Meeting
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.